Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV vaccine - GSK

Next Previous
Drug Profile

HIV vaccine - GSK

Alternative Names: 732461; 732462; GSK-732462; GSK732461; SB-732461; SB-732462

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 30 Jan 2018 GlaxoSmithKline completes a phase I trial in HIV infections in Belgium (IM) (NCT03368053)
  • 14 Dec 2017 GlaxoSmithKline initiates enrolment in a phase I trial in HIV infections in Belgium (IM) (NCT03368053)
  • 01 May 2014 GlaxoSmithKline completes a phase I follow-up trial in IV infections in Germany, France, Spain and USA (NCT01092611)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top